USS Investment Management Ltd acquired a new position in shares of AstraZeneca Plc (NYSE:AZN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 255,043 shares of the company's stock, valued at approximately $41,568,000.
Several other hedge funds have also made changes to their positions in the company. Aries Wealth Management increased its stake in AstraZeneca by 1.3% during the third quarter. Aries Wealth Management now owns 4,546 shares of the company's stock worth $741,000 after acquiring an additional 60 shares during the last quarter. Triumph Capital Management increased its position in shares of AstraZeneca by 32.6% during the third quarter. Triumph Capital Management now owns 252 shares of the company's stock valued at $41,000 after acquiring an additional 62 shares during the last quarter. Claro Advisors Inc. increased its position in shares of AstraZeneca by 5.2% during the third quarter. Claro Advisors Inc. now owns 1,247 shares of the company's stock valued at $201,000 after acquiring an additional 62 shares during the last quarter. Davis Investment Partners LLC raised its stake in shares of AstraZeneca by 3.4% in the 3rd quarter. Davis Investment Partners LLC now owns 1,868 shares of the company's stock valued at $302,000 after acquiring an additional 62 shares during the period. Finally, Riversedge Advisors LLC raised its stake in shares of AstraZeneca by 2.9% in the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company's stock valued at $379,000 after acquiring an additional 67 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Trading Down 1.9%
NYSE AZN opened at $175.34 on Friday. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The stock has a market capitalization of $271.94 billion, a PE ratio of 24.80, a price-to-earnings-growth ratio of 1.39 and a beta of 0.24. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. The firm has a 50 day moving average of $170.44 and a two-hundred day moving average of $180.08.
AstraZeneca (NYSE:AZN - Get Free Report) last issued its quarterly earnings data on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, topping the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The business had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. During the same quarter in the previous year, the firm earned $2.38 EPS. The company's revenue was up 6.5% compared to the same quarter last year. As a group, research analysts expect that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Zacks Research upgraded shares of AstraZeneca from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 13th. Weiss Ratings upgraded shares of AstraZeneca from a "hold (c+)" rating to a "buy (b-)" rating in a report on Monday, October 26th. Deutsche Bank raised AstraZeneca from a "sell" rating to a "hold" rating in a research report on Tuesday, September 15th. Nordea Equity Research raised AstraZeneca from a "sell" rating to a "buy" rating in a research report on Tuesday, October 13th. Finally, CICC Research assumed coverage on AstraZeneca in a research note on Sunday, August 23rd. They set an "outperform" rating and a $198.00 price target on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $206.67.
Get Our Latest Report on AstraZeneca
AstraZeneca Profile
(
Free Report)
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Articles
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.